236 related articles for article (PubMed ID: 31784881)
41. Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria.
Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R
Asian Pac J Cancer Prev; 2016; 17(3):1115-8. PubMed ID: 27039734
[TBL] [Abstract][Full Text] [Related]
42. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
43. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
Yap BK; Murby B
J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
[TBL] [Abstract][Full Text] [Related]
44. Usefulness of iodine-123 whole-body scan in planning iodine-131 treatment of the differentiated thyroid carcinoma in children and adolescence.
Villani MF; Grossi A; Cassano B; Pizzoferro M; Ubertini G; Longo M; Garganese MC
Nucl Med Commun; 2018 Dec; 39(12):1121-1128. PubMed ID: 30260898
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study.
Kwon SY; Lee SW; Kong EJ; Kim K; Kim BI; Kim J; Kim H; Park SH; Park J; Park HL; Oh SW; Won KS; Ryu YH; Yoon JK; Lee SJ; Lee JJ; Chong A; Jeong YJ; Jeong JH; Cho YS; Cho A; Cheon GJ; Choi EK; Hwang JP; Bae SK;
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):561-571. PubMed ID: 31820047
[TBL] [Abstract][Full Text] [Related]
46. Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial.
Qu Y; Huang R; Li L
Ann Nucl Med; 2017 Jan; 31(1):71-83. PubMed ID: 27757803
[TBL] [Abstract][Full Text] [Related]
47. Is there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?
Danilovic DLS; Coura-Filho GB; Recchia GM; Castroneves LA; Marui S; Buchpiguel CA; Hoff AO; Kopp P
Endocr Relat Cancer; 2022 Aug; 29(8):475-483. PubMed ID: 35613335
[TBL] [Abstract][Full Text] [Related]
48. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
49. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.
Blumhardt R; Wolin EA; Phillips WT; Salman UA; Walker RC; Stack BC; Metter D
Endocr Relat Cancer; 2014; 21(6):R473-84. PubMed ID: 25277792
[TBL] [Abstract][Full Text] [Related]
50. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
[TBL] [Abstract][Full Text] [Related]
51. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
52. Referral Practice for Radioactive Iodine Ablation (RAI) after ATA guidelines 2015: results from a Tertiary Cancer Care Centre.
Dhar H; Thiagarajan S; Yousuf A; Nayyar SS; Chaukar D
Eur Arch Otorhinolaryngol; 2020 Sep; 277(9):2521-2526. PubMed ID: 32240364
[TBL] [Abstract][Full Text] [Related]
53. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
54. Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?
Gallicchio R; Giacomobono S; Capacchione D; Nardelli A; Barbato F; Nappi A; Pellegrino T; Storto G
Endocrine; 2013 Oct; 44(2):426-33. PubMed ID: 23536285
[TBL] [Abstract][Full Text] [Related]
55. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
[TBL] [Abstract][Full Text] [Related]
56. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
57. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
[TBL] [Abstract][Full Text] [Related]
58. Response to Surgery Assessments for Sparing Radioiodine Remnant Ablation in Intermediate-Risk Papillary Thyroid Cancer.
Zhang X; Liu JR; Mu ZZ; Cheng XQ; Lin YS
J Clin Endocrinol Metab; 2023 May; 108(6):1330-1337. PubMed ID: 36567646
[TBL] [Abstract][Full Text] [Related]
59. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
60. The value of the first postoperative diagnostic I-131 scan in patients with papillary thyroid carcinoma.
Ran B; Shang J; Chen Y; Zhou M; Li H; He W; Li Y; Cai Q; Guo B; Gong J; Xu H
J Cancer Res Clin Oncol; 2024 Feb; 150(2):80. PubMed ID: 38319395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
